Updated 02:01 GMT, 17 Nov 2026 SPX 7,416.59 -1.92% NDX 27,197.15 -2.67% VIX 22.91 +18.70% GOLD 3,868.50 -0.46% CL 85.14 -3.86% BTC 65,305.22 0.00%
NAS100 27,197 −2.67% S&P 7,417 −1.92% GOLD $3,869 −0.46% BTC $65,305 VIX 22.91 +18.70% latest tape · as of 02:01 UTC
The Screen · Healthcare · Packaged Foods

Clene Inc

CLNN · NASDAQ · USD · Market cap $76M · 76 employees

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.

FAIL · Does not pass the screen
3.92 USD

Price as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago

Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price3.92 USD at the 13 Nov 2026 close
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 1.17)
  • Last reviewed13 Nov 2026 (4 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-13).

Current read
Accumulation ?
Screened · screened 2026-11-13
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 1.17, read 2026-11-09
  • Ethical does not pass the values gate
Price3.92 USD
Ethical score70.0/100
Our investment reviews on this name
2026-11-13Read Accumulation4.00-2.0% to today Markdown gives way to Accumulation
2026-11-06Read Markdown3.97-1.3% to today ✓Accumulation gives way to Markdown first Markdown read since October
2026-10-30Read Accumulation3.90+0.5% to today ✓Markdown gives way to Accumulation after an 18% rise in 12 days
2026-10-18Read Markdown3.31+18.6% to today Markup gives way to Markdown after a 27% slide in 7 days

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Clene Inc holds its Accumulation at $3.92. The statistical read favours the sellers, held for 43 days.

As held on the ledger · 2026-11-13
PhaseAccumulation
Quantitative stateThe statistical read favours the sellers, held for 43 days
Price at the screen$3.92
ValuationN/A trailing · -3.31 forward price to earnings
Values screenFAIL · score 70.0
Beta0.92
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 119.54% Below 33% Interest-bearing debt is 119.5% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 28.62% Below 49% Money owed to the company is 28.6% of assets, under the 49% limit. Pass
Revenue purity 100.00% Below 5% 100.0% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Clene's business is in a permissible area, but its interest-bearing debt is about 120% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when CLNN's ethical verdict changes

Today CLNN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

How a fair value is estimated: discounted cash flow (DCF).

The Street's Range
20.00Street low 30.00Street average 50.00Street high 3.92Price

Third-party analyst targets. The average target sits +665% from the screen price.

Price History & Projections

Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-3.3x
EPS, trailing-3.25
EPS, forward-1.79
Revenue growth-81.5%revenue is shrinking
Profit margin0.0%currently unprofitable
FCF yield-15.30%
Current ratio1.94healthy short-term liquidity
Beta0.92steadier than the market
Short interest, float0.10%
52-week range3.25 - 13.50
MoatNONE
Market cap$76M
Employees76

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

CLNN trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-13 Accumulation · changed $4.00 +0.8% Entry 11

The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $32.

2026-11-06 Markdown · changed $3.97 +1.8% Entry 10

The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $32.

2026-10-30 Accumulation · changed $3.90 +18.0% Entry 9

The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 18.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $32.

2026-10-18 Markdown · changed $3.31 -27.2% Entry 8

The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 27.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $32.

2026-10-11 Markup · changed $4.54 +0.0% Entry 7

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $32.

2026-10-02 Distribution · changed $4.54 -23.3% Entry 6

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 23.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $32.

2026-08-25 Markdown $5.92 +0.0% Entry 5

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $32.

2026-07-25 Markdown $5.92 +1.4% Entry 4

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $32.

2026-07-18 Markdown $5.84 +0.0% Entry 3

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (5 analysts) rates it none, with a mean price target of $32.

2026-07-03 Markdown $5.84 +0.0% Entry 2

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in CLNN's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $6.50 -15.0% · $850 -15.0%
2 months $6.11 -9.6% · $904 -9.6%
3 months $5.92 -6.7% · $933 -6.7%
6 months $6.88 -19.7% · $803 -19.7%
1 year $4.26 +29.7% · $1,297 +29.7%
2 years $8.60 -35.8% · $642 -35.8%
3 years $20.60 -73.2% · $268 -73.2%
5 years $222.80 -97.5% · $25 -97.5%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever CLNN does next, these words stay.

Clene Inc · CLNN · Accumulation · $3.92
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.